MZ, AZV, NU23-08-00071, Geneticky snížená exprese imunitního kontrolního bodu LAIR-1 u tumor specifických T buněk jako nová strategie k překonání rezistence pevných nádorů k adoptivní T buněčné imunoterapii, 2023–2026

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Fakultní nemocnice Motol)

Spoluřešitel: MUDr. Luca Vannucci, Ph.D. (Mikrobiologický ústav AV ČR)

MZ, AZV, NU23J-08-00031, Kombinované možnosti léčby měkkotkáňových sarkomů za účelem překonání rezistence k imunoterapii, 2023–2026

Hlavní řešitel: MUDr. Zuzana Střížová, Ph.D. (Fakultní nemocnice Motol)

MZ, AZV, NU22-03-00300, LL-37 jako nový silný molekulární nástroj pro zvýšení účinnosti ex vivo připravených dendritických buněk v imunoterapii urogenitálních karcinomů, 2022–2025 (prodlouženo do 2026)

Hlavní řešitel: Prof. MUDr. Jiřina Bartůňková, Ph.D., MBA (Fakultní nemocnice Motol)

Spoluřešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

TA ČR, SIGMA 4 (Univerzita Karlova), TQ11000058, Nový model metastatických linií nediferencovaného pleomorfního sarkomu, 04–11/2025,

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

TA ČR, GAMA 2 (Univerzita Karlova), 202104/TP01010040, Nová buněčná linie nediferencovaného pleomorfního sarkomu, 2021–2022

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

GA UK, 364218, Izolace, charakterizace a expanze subpopulací lymfocytů infiltrujících nádory ledvin pro vývoj adoptivní buněčné imunoterapie, 2018–2020

Hlavní řešitel: MUDr. Zuzana Střížová, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

Školitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

UK, PRIMUS/MED/12, Příprava polyklonálních cytologických T buněk pro adoptivní buněčnou imunoterapii nádorových onemocnění, 2017–2019

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

MZ, AZV, 16-28135A, Příprava polyklonálních nádorově specifických T buněk pro adoptivní buněčnou imunoterapii karcinomu prostaty, 2016–2019

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

Spoluřešitel: Prof. MUDr. Jiřina Bartůňková, Ph.D., MBA (Fakultní nemocnice Motol)

Taborska, P., D. Stakheev, K. Krausova, J. Bartunkova, and D. Smrz*. 2026. High Concentrations of β2-Microglobulin Do Not Inhibit In Vitro Generation of Functional Dendritic Cells. Journal of immunology research 2026:2924555. DOI: 10.1155/jimr/2924555 (*corresponding; IF 3.6; Q2; D5).

Taborska, P., D. Stakheev, and D. Smrz*. 2026. Dual role of IFNgamma in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity. Oncology letters 31:78. DOI: 10.3892/ol.2025.15431 (*corresponding; IF 2.2; Q3; D7).

Benesova, I^†., K. Kalkusova^†, Y. S. Kwon, P. Taborska, D. Stakheev, K. Krausova, J. Smetanova, A. Ozaniak, J. Bartunkova, D. Smrz*, and Z. O. Strizova. 2025. Cancer‑associated fibroblasts in human malignancies, with a particular emphasis on sarcomas (Review). International journal of oncology 67. DOI: 10.3892/ijo.2025.5785 (*corresponding, ^†first; IF 4.9; Q1; D3).

Sushytskyi, L., A. Synytsya, P. Lukac, L. Rajsiglova, P. Capek, R. Pohl, R. Bleha, L. E. Vannucci, D. Smrz, J. Copikova, and P. Kastanek. 2025. Immunologically active cell wall polysaccharides of green microalga Dictyosphaerium chlorelloides (Chlorellacea). Carbohydrate polymers 353:123242. DOI: 10.1016/j.carbpol.2025.123242 (IF 12.5; Q1; D1).

Rajsiglova, L., M. Babic, K. Krausova, P. Lukac, K. Kalkusova, P. Taborska, L. Sojka, J. Bartunkova, D. Stakheev, L. Vannucci, and D. Smrz*. 2024. Immunogenic properties of nickel-doped maghemite nanoparticles and the implication for cancer immunotherapy. Journal of immunotoxicology 21:2416988. DOI: 10.1080/1547691X.2024.2416988 (*corresponding; IF 3.1; Q2; D5).

Kalkusova, K., P. Taborska, D. Stakheev, M. Rataj, S. Smite, E. Darras, J. Albo, J. Bartunkova, L. Vannucci, and D. Smrz*. 2024. Impaired Proliferation of CD8(+) T Cells Stimulated with Monocyte-Derived Dendritic Cells Previously Matured with Thapsigargin-Stimulated LAD2 Human Mast Cells. Journal of immunology research 2024:5537948.  DOI: 10.1155/2024/5537948 (*corresponding; IF 3.6; Q2; D5).

Patent, Úřad průmyslového vlastnictví ČR, č. 310055 – Buněčná linie a její použití, majitel patentu: Univerzita Karlova, původci: Doc. RNDr. Daniel Smrž, Ph.D. a Ing. Pavla Táborská, Ph.D. [přechodná mezinárodní ochrana uplatněna: PCT/CZ2023/050092, WO 2024/132002 A1, Univerzita Karlova]

Borcinova, M., R. Bartolini, L. K. Foley, V. Novak, P. Taborska, D. Stakheev, M. Rataj, D. Smrz, M. Fialova, J. Hacek, M. Komarc, S. Vesely, M. Babjuk, I. Striz, J. Bartunkova, T. Buchler, and Z. Ozaniak Strizova*. 2024. Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma. Translational oncology 42:101891. DOI:10.1016/j.tranon.2024.101891 (*corresponding, IF 4.5; Q1; D3).

Taborska, P., P. Lukac, D. Stakheev, L. Rajsiglova, K. Kalkusova, K. Strnadova, L. Lacina, B. Dvorankova, J. Novotny, M. Kolar, M. Vrana, H. Cechova, S. Ransdorfova, M. Valerianova, K. Smetana, Jr., L. Vannucci, and D. Smrz*. 2023. Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy. Scientific reports 13:19079. DOI: 10.1038/s41598-023-46305-7 (*corresponding; IF 3.8; Q1; D2).

Stakheev, D., P. Taborska, K. Kalkusova, J. Bartunkova, and D. Smrz*. 2022. LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy. Pharmaceutics 14. DOI: 10.3390/pharmaceutics14122747 (*corresponding; IF 5.4; Q1, D2).

Kalkusova, K., P. Taborska, D. Stakheev, and D. Smrz*. 2022. The Role of miR-155 in Antitumor Immunity. Cancers 14. DOI: 10.3390/cancers14215414 (*corresponding; IF 5.2; Q1; D3).

Kalkusova, K., S. Smite, E. Darras, P. Taborska, D. Stakheev, L. Vannucci, J. Bartunkova, and D. Smrz*. 2022. Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors. International journal of molecular sciences 23. DOI: 10.3390/ijms231911080 (*corresponding; IF 5.6; Q1; D3).

Podrazil, M., P. Taborska, D. Stakheev, M. Rataj, J. Lastovicka, A. Vlachova, P. Pohunek, J. Bartunkova, and D. Smrz*. 2022. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. Frontiers in immunology 13:892277. DOI: 10.3389/fimmu.2022.892277 (*corresponding; IF 7.3; Q1; D3).

Bugajev, V., T. Paulenda, P. Utekal, M. Mrkacek, I. Halova, L. Kuchar, O. Kuda, P. Vavrova, B. Schuster, S. Fuentes-Liso, L. Potuckova, D. Smrz, S. Cernohouzova, L. Draberova, M. Bambouskova, and P. Draber. 2021. Crosstalk between ORMDL3, serine palmitoyltransferase, and 5-lipoxygenase in the sphingolipid and eicosanoid metabolic pathways. J Lipid Res:100121. 10.1016/j.jlr.2021.100121 (IF 6.6; Q1; D3).

Taborska, P., J. Lastovicka, D. Stakheev, Z. Strizova, J. Bartunkova, and D. Smrz*. 2021. SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors. Immunity, inflammation and disease.10.1002/iid3.496 (*corresponding; IF 2.4; Q4; D9).

Bezdicka, M., P. Kleiblova, J. Soucek, M. Borecka, E. El-Lababidi, D. Smrz, M. Rataj, Z. Sumnik, J. Malikova, and O. Soucek. 2021. Novel presentation of the c.1856A > G (p.Asp619Gly) TSHR gene-activating variant: relapsing hyperthyroidism in three subsequent generations manifesting in early childhood and an in vitro functional study. Hormones.10.1007/s42000-021-00299-x (IF 3.4; Q3; D7).

Taborska, P., Z. Strizova, D. Stakheev, L. Sojka, J. Bartunkova, and D. Smrz*. 2021. CD4(+) T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein. Frontiers in immunology 12:629102.10.3389/fimmu.2021.629102 (*corresponding; IF 8.8; Q1; D3).

Taborska, P., D. Stakheev, J. Bartunkova, and D. Smrz*. 2021. Thapsigargin-Stimulated LAD2 Human Mast Cell Line Is a Potent Cellular Adjuvant for the Maturation of Monocyte-Derived Dendritic Cells for Adoptive Cellular Immunotherapy. International journal of molecular sciences 22. 22.10.3390/ijms22083978 (*corresponding; IF 6.2; Q1; D3).

Snajdauf, M., K. Havlova, J. Vachtenheim, Jr., A. Ozaniak, R. Lischke, J. Bartunkova, D. Smrz, and Z. Strizova*. 2021. The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Frontiers in molecular biosciences 8:628332. 10.3389/fmolb.2021.628332 (*corresponding; IF 6.1; Q1; D3).

Strizova, Z., M. Kuchar, L. Capkova, M. Komarc, J. Skrivan, J. Bartunkova, J. Plzak, and D. Smrz*. 2021. Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response. Biomedicines 9. 10.3390/biomedicines9040402 (*corresponding; IF 4.7; Q2; D5).

Mucciolo, G., C. Curcio, C. Roux, W. Y. Li, M. Capello, R. Curto, R. Chiarle, D. Giordano, M. A. Satolli, R. Lawlor, A. Scarpa, P. Lukac, D. Stakheev, P. Provero, L. Vannucci, T. W. Mak, F. Novelli, and P. Cappello. 2021. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Proc Natl Acad Sci U S A 118. DOI: 10.1073/pnas.2020395118 (IF 12.7; Q1; D2).

Kuchar, M., Z. Strizova*, L. Capkova, M. Komarc, J. Skrivan, J. Bartunkova, D. Smrz, and J. Plzak. 2021. The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay. Biomedicines 9. DOI: 10.3390/biomedicines9020097 (*corresponding, IF 4.7; Q2; D5).

Taborska, P., D. Stakheev, H. Svobodova, Z. Strizova, J. Bartunkova, and D. Smrz*. 2020. Acute Conditioning of Antigen-Expanded CD8(+) T Cells via the GSK3beta-mTORC Axis Differentially Dictates Their Immediate and Distal Responses after Antigen Rechallenge. Cancers 12. 10.3390/cancers12123766 (*corresponding, IF 6.6; Q1; D3).

Strizova, Z*., D. Smrz, and J. Bartunkova. 2020. Response to Weiss MF re: "Seroprevalence of Borrelia IgM and IgG Antibodies in Healthy Individuals: A Caution Against Serology Misinterpretations and Unnecessary Antibiotic Treatments". Vector Borne Zoonotic Dis. 10.1089/vbz.2020.2690 (*corresponding, IF 2.1; Q4; D9).

Strizova, Z., J. Vachtenheim, Jr., M. Snajdauf, R. Lischke, J. Bartunkova, and D. Smrz*. 2020. Tumoral and paratumoral NK cells and CD8(+) T cells of esophageal carcinoma patients express high levels of CD47. Scientific reports 10:1393 (*corresponding, IF 4.3; Q1; D2).

Ozaniak, A., Z. Strizova, P. Hladik, and R. Lischke. 2020. Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy. Cancer 126:4068-4069

Strizova, Z.*, J. Bartunkova, and D. Smrz. 2020. Can wearing face masks in public affect transmission route and viral load in COVID-19? Central European journal of public health 28:161-162 (*corresponding, IF 1.1; Q4; D10).

Paces, J., Z. Strizova*, D. Smrz, and J. Cerny. 2020. COVID-19 and the immune system. Physiological research. 10.33549/physiolres.934492 (*corresponding, IF 1.8; Q4; D9).

Strizova, Z., M. Snajdauf, D. Stakheev, P. Taborska, J. Vachtenheim, Jr., J. Biskup, R. Lischke, J. Bartunkova, and D. Smrz*. 2020. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients. Journal of cancer research and clinical oncology 146:1979-1992 (*corresponding, IF 4.5; Q2; D5).

Strizova, Z., T. Milota, and J. Bartunkova. 2020. COVID-19 from the perspective of an immunologist. Casopis lekaru ceskych 159:67-71

Strizova, Z.*, D. Smrz, and J. Bartunkova. 2020. Seroprevalence of Borrelia IgM and IgG Antibodies in Healthy Individuals: A Caution Against Serology Misinterpretations and Unnecessary Antibiotic Treatments. Vector Borne Zoonotic Dis. 10.1089/vbz.2020.2632 (*corresponding, IF 2.1; Q4; D9).

Tobio, A., G. Bandara, D. A. Morris, D. K. Kim, M. P. O'Connell, H. D. Komarow, M. C. Carter, D. Smrz, D. D. Metcalfe, and A. Olivera. 2020. Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. Haematologica 105:124-135 (IF 9.9; Q1; D1).

Kuchar, M., Z. Strizova, M*. Votava, and J. Plzak. 2019. The relevance of Fas/Fas ligand axis in the tumor microenvironment of salivary gland adenoid cystic carcinoma. Oral oncology 97:135-136 (*corresponding, IF 3.9; Q1; D1).

Strizova, Z.*, J. Vachtenheim, Jr., and J. Bartunkova. 2019. The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression. Breast Cancer Res Treat 178:247-248 (*corresponding, IF 3.8; Q2; D4).

Strizova, Z., J. Bartunkova, and D. Smrz*. 2019. The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma. Cancer immunology, immunotherapy : CII 68:1831-1838 (*corresponding, IF 5.4; Q1; D3).

Strizova, Z., P. Taborska, D. Stakheev, S. Partlova, K. Havlova, S. Vesely, J. Bartunkova, and D. Smrz*. 2019. NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma. Urologic oncology 37:503-509 (*corresponding, IF 2.8; Q3; D6).

Stakheev, D., P. Taborska, Z. Strizova, M. Podrazil, J. Bartunkova, and D. Smrz*. 2019. The WNT/beta-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. Scientific reports 9:4761 (*corresponding, IF 4.0; Q1; D3).

Strizova, Z.*, O. Patek, L. Vitova, M. Horackova, and J. Bartunkova. 2019. Internet-based self-diagnosis of Lyme disease caused death in a young woman with systemic lupus erythematosus. Joint, bone, spine : revue du rhumatisme 86:650-651 (*corresponding, IF 3.7; Q2; D4).

Taborska, P., J. Bartunkova, and D. Smrz*. 2018. Simultaneous in vitro generation of human CD34(+)-derived dendritic cells and mast cells from non-mobilized peripheral blood mononuclear cells. J Immunol Methods 458:63-73 (*corresponding, IF 1.9; Q3; D7).

Taborska, P., D. Stakheev, Z. Strizova, K. Vavrova, M. Podrazil, J. Bartunkova, and D. Smrz*. 2017. Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients. Medical oncology 34:173 (*corresponding, IF 2.9; Q3; D6).